Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
about
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best PracticeThe Treatment of Autosomal Dominant Polycystic Kidney DiseaseAutosomal dominant polycystic kidney disease: recent advances in clinical managementScreening for Unruptured Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease: A Survey of 420 NephrologistsIdentifying and integrating consumer perspectives in clinical practice guidelines on autosomal-dominant polycystic kidney disease.Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy.Serum calcitriol levels in a patient with X-linked hypophosphatemia complicated by autosomal dominant polycystic kidney disease.Patient Survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey.Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney DiseaseTemporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients.Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review.Diagnostic Algorithm in the Management of Acute Febrile Abdomen in Patients with Autosomal Dominant Polycystic Kidney Disease.Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.Volume regression of native polycystic kidneys after renal transplantation.Native Nephrectomy in Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease.Peritoneal dialysis for autosomal dominant polycystic kidney disease: a retrospective study.A cAMP and CREB-mediated feed-forward mechanism regulates GSK3β in polycystic kidney disease.Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patientsTolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.Clinical Trials in Pediatric Autosomal Dominant Polycystic Kidney Disease.Pancreatic Cysts in Autosomal Dominant Polycystic Kidney Disease: Prevalence and Association with PKD2 Gene Mutations.Biliary Tract and Liver Complications in Polycystic Kidney Disease.Clinical Trials and a View Toward the Future of ADPKD.B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study.Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.Hepatic cyst penetration of cefazolin in patients receiving aspiration sclerotherapy.PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.Recent advances in autosomal-dominant polycystic kidney disease.Diagnostic Evaluation as a Biomarker in Patients with ADPKD.ADPKD: clinical issues before and after renal transplantation.Clinical Manifestation and Management of ADPKD in Western Countries.Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: prevalence, risk of rupture, and management. A systematic review.Animal models of biliary injury and altered bile acid metabolism.Effect of renal transcatheter arterial embolization on quality of life in patients with autosomal dominant polycystic kidney disease.Generation and phenotypic characterization of Pde1a mutant mice.The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives.Combined renin-angiotensin-aldosterone system blockade and statin therapy effectively reduces the risk of cerebrovascular accident in autosomal dominant polycystic kidney disease: a nationwide population-based cohort study.Clinicians' attitude towards family planning and timing of diagnosis in autosomal dominant polycystic kidney disease.
P2860
Q26767011-64000CAD-EB7A-4F58-886F-30CB0BBB5286Q28077060-7024F701-53CD-43B6-BC69-C1777AD7A830Q28079782-78B274EF-862F-4D6B-A7EE-9A3F770EACC2Q28601031-CE041F00-2EAF-42A6-A176-E4399BDB8945Q30203008-344CFAFB-47A3-4890-8202-205CA4E617E6Q33627670-7A3ABBD0-0960-40F7-A8E0-126C3663E893Q33710251-036CC618-9205-4F8A-9524-8E65499E4B94Q33783023-ED1320E8-12AD-4623-B247-55B0025356ACQ33873062-FC1CBFFA-3A28-4513-979C-1790ECC671D9Q33910788-E4A512AD-6C52-44A2-8809-2656FF23E533Q35933508-41B0BEF6-7E4B-4385-B7C7-F3E341408FA7Q36104948-75D86AD2-76E1-46DD-A117-5DC8BA0B41DCQ36323939-1706C6B6-5BCE-4E8D-8B9A-11767DCFD8DBQ36435509-564E0709-BD24-426C-BB41-86EBF505CE3BQ36678556-F27B2B28-60F9-4334-A837-359F5ABAFA34Q36906107-D184F38E-EB2C-48BE-89B5-9ED184B1B2EEQ37529873-418D7FE2-BB69-42CF-88DE-918DC7EC5080Q37606169-EE64D40B-EE7F-4E38-ACE2-05A079A9D9D1Q38593001-296A4ECA-CEE3-4746-870C-8CED15B92DD7Q38652031-B9B131AD-B153-4389-B56B-36AF7176A0A0Q38733796-3CDDD195-D72E-48E0-8EBB-6D5032B84473Q38798559-A0B9D3FA-CA8C-4637-8E77-27121517CB97Q38808055-2347132A-6922-4B84-A5BF-9AAE7360B7ECQ38812543-7A36A4C8-190E-4986-9ABB-FAFA2B469213Q38833791-33491ED0-22BD-4868-BF02-97EA0E6419B0Q38848641-C8432AD8-2EB9-41A3-A6A4-DD86F27C352DQ38853071-E1ED3A4A-10A2-4272-A8D3-F797E836779EQ38860122-4C3B5CD5-7925-4081-AB09-BF40EBDC130FQ38868452-D3547D3D-F115-4F25-84DA-341E2797D9D8Q38935264-B0C42649-9230-4E11-BDE6-0BBB7E43860BQ38978474-563D97AC-03F2-4820-AEE1-5A7CCEDF9AB5Q38987102-C4E38BF6-6B9A-4F8D-BECC-2DAE1825182DQ39030254-6B9B23F6-3DAC-4921-99D6-06E746699BC8Q39173664-48BC11E2-5069-4389-B012-5A1C14DEFB87Q39436033-22A704C6-7D8D-4626-976C-5E275BD2DE8EQ40040634-699FC7C0-77CD-485B-8184-58E97FE732C0Q41153428-E724322A-C198-401A-A684-845EC9E18063Q41998074-D7BEF8EA-9FD1-4076-A044-35C930D4B964Q42119273-0F2B76AE-5100-494F-888C-D1AFD2D1767EQ42367550-9A618EA3-ADEC-42CB-8F20-D56CBDC91B67
P2860
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Autosomal-dominant polycystic ...... IGO) Controversies Conference.
@ast
Autosomal-dominant polycystic ...... IGO) Controversies Conference.
@en
Autosomal-dominant polycystic kidney disease
@nl
type
label
Autosomal-dominant polycystic ...... IGO) Controversies Conference.
@ast
Autosomal-dominant polycystic ...... IGO) Controversies Conference.
@en
Autosomal-dominant polycystic kidney disease
@nl
prefLabel
Autosomal-dominant polycystic ...... IGO) Controversies Conference.
@ast
Autosomal-dominant polycystic ...... IGO) Controversies Conference.
@en
Autosomal-dominant polycystic kidney disease
@nl
P2093
P2860
P50
P356
P1433
P1476
Autosomal-dominant polycystic ...... DIGO) Controversies Conference
@en
P2093
Arlene B Chapman
Bertram L Kasiske
Conference Participants
David C Wheeler
Kai-Uwe Eckardt
Olivier Devuyst
Ron T Gansevoort
Ronald D Perrone
Shigeo Horie
Terry Watnick
P2860
P2888
P356
10.1038/KI.2015.59
P407
P577
2015-03-18T00:00:00Z
P5875
P6179
1046010918